A phase II study combining gemcitabine and carboplatin in patients with platinum-resistant ovarian cancer

A phase II study combining gemcitabine and carboplatin in patients with platinum-resistant ovarian cancer - A phase II study combining gemcitabine and carboplatin in patients with platinum-resistant ovarian cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019225

Enrollment

Registered

2015-10-05

Start date

2015-10-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with platinum-resistant ovarian cancer

Interventions

We choice the combination of gemcitabine and carboplatin as the regimen of chemotherapy in platinum-resistant ovarian cancer. We throw the chemotherapy once per 3 weeks. Day1: gemcitabine 800mg/m2+C

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: patients in platinum-resistant ovarian cancer who were given the combination of paclitaxel and carboplatin as prior chemotherapy

Exclusion criteria

Exclusion criteria: The organization type including sarcoma

Design outcomes

Primary

Measure	Time frame
clinical responce	—

Secondary

Measure	Time frame
side effect	—

Countries

Japan

Contacts

Public ContactSatoe Fujiwara

The Osaka medical coledge Gynecologic oncology

gyn092@poh.osaka-med.ac.jp972-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026